New agents, new treatment, and antiemetic therapy

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

With the introduction of newer antineoplastic agents, the challenge for supportive care is enlarging. For the most part, these targeted therapies are given in addition to more classic anticancer drugs, either in combination or in sequence, underscoring the need for prevention of emesis and attention to all treatment toxicities. Strategies for preventing these side effects need to be investigated while appropriately addressing more familiar problems such as emesis. Two directions for improving emetic control are clear. First is the development of newer antiemetics that enhance current control rates, and second is the proper use of existing agents in all emetic settings. This report outlines the rationale behind the development of neurokinin type I antagonists, and reviews consensus recommendations in the prevention of acute and delayed emesis.

Original languageEnglish (US)
Pages (from-to)119-124
Number of pages6
JournalSeminars in Oncology
Volume29
Issue number1 SUPPL. 4
StatePublished - 2002
Externally publishedYes

Fingerprint

Antiemetics
Emetics
Vomiting
Antineoplastic Agents
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology

Cite this

New agents, new treatment, and antiemetic therapy. / Gralla, Richard J.

In: Seminars in Oncology, Vol. 29, No. 1 SUPPL. 4, 2002, p. 119-124.

Research output: Contribution to journalArticle

@article{cb3ce94d9b674e4597447b9a58360508,
title = "New agents, new treatment, and antiemetic therapy",
abstract = "With the introduction of newer antineoplastic agents, the challenge for supportive care is enlarging. For the most part, these targeted therapies are given in addition to more classic anticancer drugs, either in combination or in sequence, underscoring the need for prevention of emesis and attention to all treatment toxicities. Strategies for preventing these side effects need to be investigated while appropriately addressing more familiar problems such as emesis. Two directions for improving emetic control are clear. First is the development of newer antiemetics that enhance current control rates, and second is the proper use of existing agents in all emetic settings. This report outlines the rationale behind the development of neurokinin type I antagonists, and reviews consensus recommendations in the prevention of acute and delayed emesis.",
author = "Gralla, {Richard J.}",
year = "2002",
language = "English (US)",
volume = "29",
pages = "119--124",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "1 SUPPL. 4",

}

TY - JOUR

T1 - New agents, new treatment, and antiemetic therapy

AU - Gralla, Richard J.

PY - 2002

Y1 - 2002

N2 - With the introduction of newer antineoplastic agents, the challenge for supportive care is enlarging. For the most part, these targeted therapies are given in addition to more classic anticancer drugs, either in combination or in sequence, underscoring the need for prevention of emesis and attention to all treatment toxicities. Strategies for preventing these side effects need to be investigated while appropriately addressing more familiar problems such as emesis. Two directions for improving emetic control are clear. First is the development of newer antiemetics that enhance current control rates, and second is the proper use of existing agents in all emetic settings. This report outlines the rationale behind the development of neurokinin type I antagonists, and reviews consensus recommendations in the prevention of acute and delayed emesis.

AB - With the introduction of newer antineoplastic agents, the challenge for supportive care is enlarging. For the most part, these targeted therapies are given in addition to more classic anticancer drugs, either in combination or in sequence, underscoring the need for prevention of emesis and attention to all treatment toxicities. Strategies for preventing these side effects need to be investigated while appropriately addressing more familiar problems such as emesis. Two directions for improving emetic control are clear. First is the development of newer antiemetics that enhance current control rates, and second is the proper use of existing agents in all emetic settings. This report outlines the rationale behind the development of neurokinin type I antagonists, and reviews consensus recommendations in the prevention of acute and delayed emesis.

UR - http://www.scopus.com/inward/record.url?scp=0036124257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036124257&partnerID=8YFLogxK

M3 - Article

VL - 29

SP - 119

EP - 124

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 1 SUPPL. 4

ER -